Vaccination against sexually transmitted infections

Current Opinion in Infectious Diseases

Volumn 25, Issue 1, 2012, Pages 66-72

  Fairley, Christopher K ^a   Read, Tim R H ^a  

^a MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

Author keywords

Control; Hepatitis A; Hepatitis B; Human papillomavirus; Vaccine

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE; WART VIRUS VACCINE;

AGE; AUSTRALIA; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CONDYLOMA ACUMINATUM; EPIDEMIC; HEPATITIS A; HEPATITIS B; HETEROSEXUALITY; HUMAN; INFECTION CONTROL; MALE HOMOSEXUAL; PAPILLOMAVIRUS INFECTION; REVIEW; SEXUAL TRANSMISSION; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

FEMALE; HEPATITIS A; HEPATITIS B; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUALLY TRANSMITTED DISEASES, VIRAL; VACCINATION; VIRAL HEPATITIS VACCINES;

EID: 84155171155     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834e9aeb     Document Type: Review

References (57)

1. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44.
2. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85:499-502.
3. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis: United States, 2007. MMWR Surveill Summ 2009; 58:1-27.
4. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347:1652-1661.
5. Howie SE, Horner PJ, Horne AW, Entrican G. Immunity and vaccines against sexually transmitted Chlamydia trachomatis infection. Curr Opin Infect Dis 2011; 24:56-61.
6. Schiller JT, Lowy DR. Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol 2010; 64:23-41.
7. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. J Am Med Assoc 1994; 271:1328-1334.
8. Sharapov UM. Infectious diseases related to travel. In: Brunette GW, Kozarsky PE, Magill AJ, et al., editors. The Yellow Book 2012. New York: Oxford University Press; 2012. pp. 134-350.
9. Sohn N, Robilotti JG Jr. The gay bowel syndrome. A review of colonic and rectal conditions in 200 male homosexuals. Am J Gastroenterol 1977; 67:478-484.
10. Ferson MJ, Young LC, Stokes ML. Changing epidemiology of hepatitis A in the 1990 s in Sydney, Australia. Epidemiol Infect 1998; 121:631-636.
11. Girardi E, Scognamiglio P, Sciarrone MR, et al. High HIV prevalence in male patients with acute hepatitis A in the Rome metropolitan area, Italy 2002-2008. J Hepatol 2011; 54:1102-1106.
12. Perez-Sautu U, Costafreda MI, Cayla J, et al. Hepatitis A virus vaccine escape variants and potential new serotype emergence. Emerg Infect Dis 2011;17:734-737.
13. Roome AJ, Walsh SJ, Cartter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. J Am Med Assoc 1993;270:2931-2934.
14. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs. standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. J Am Med Assoc 2011; 305:1432-1440.
15. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. J Am Med Assoc 1990; 263:1218-1222.
16. National Notifiable Diseases Surveillance System - Australian Government - Department of Health and Ageing [Online]. 2008. http://www9.health.gov.au/cda/ source/cda-index.cfm [accessed 11 September 2008].
17. Health Protection Agency [Online]. 2008. http://www.hpa.org.uk/ [accessed September 2008].
18. Van Rijckevorsel GG, Sonder GJ, Bovee LP, et al. Trends in hepatitis A, B, and shigellosis compared with gonorrhea and syphilis in men who have sex with men in Amsterdam, 1992-2006. Sex Transm Dis 2008; 35:930-934.
19. van Houdt R, Bruisten SM, Geskus RB, et al. Ongoing transmission of a single hepatitis B virus strain among men having sex with men in Amsterdam. J Viral Hepat 2010; 17:108-114.
20. Baars JE, Boon BJ, Garretsen HF, van de Mheen D. The reach of a hepatitis B vaccination programme among men who have sex with men. Eur J Public Health 2011; 21:333-337.
21. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1-33; quiz CE1-4.
22. Goilav C, Piot P. Vaccination against hepatitis B in homosexual men. A review. Am J Med 1989; 87:21S-25S.
23. Schreeder MT, Thompson SE, Hadler SC, et al. Hepatitis B in homosexual men: prevalence of infection and factors related to transmission. J Infect Dis 1982; 146:7-15.
24. Andersson MI, Low N, Irish CJ, et al. Investigation of a large community-based outbreak of hepatitis B infection in the United Kingdom. Epidemiol Infect 2011 [Epub ahead of print].
25. The Green Book - Immunisation against infectious disease. Third edn. London, United Kingdom: Department of Health. [Online]. 2011. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-079917 [accessed 31 August 2001].
26. Horvat RT. Diagnostic and clinical relevance of HBV mutations. Lab Med 2011; 42:488-496.
27. Hsu HY, Chang MH, Ni YH, et al. No increase in prevalence of hepatitis B surface antigenmutant in a population of children and adolescentswhowere fully covered by universal infant immunization. J Infect Dis 2010; 201:1192-1200.
28. Chang MH. Breakthrough HBV infection in vaccinated children in Taiwan: surveillance for HBV mutants. Antivir Ther 2010; 15:463-469.
29. Locarnini SA, Yuen L. Molecular genesis of drug-resistant and vaccineescape HBV mutants. Antivir Ther 2010; 15:451-461.
30. Kingsley LA, Rinaldo CR, Lyter DW, et al. Sexual transmission efficiency of hepatitis B virus and human immunodeficiency virus among homosexual men. J Am Med Assoc 1990; 264:230-234.
31. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185:251-257.
32. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-2170.
33. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-1943.
34. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-314.
35. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373:1949-1957.
36. Harper DM. Preliminary HPV vaccine results for women older than 25 years. Lancet 2009; 373:1921-1922.
37. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. The FUTURE II Study Group. N Engl J Med 2007; 356:1915-1927.
38. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/ 18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009; 2:868-878.
39. Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011;105:28-37.
40. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926-935.
41. GARDASIL1 [Product Information]. South Granville, New South Wales: Merck Sharp & Dohme (Australia) Pty Limited; 18 July 2011.
42. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364:401-411.
43. Palefsky J. Can HPV vaccination help to prevent anal cancer? Lancet Infect Dis 2010; 10:815-816.
44. Palefsky J. Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men. 26th International Papillomavirus Conference & Clinical and Public Health Workshops. Montreal, Canada; 2010.
45. Global Plan of Action for New and Under-Utilized Vaccine Implementation: 2010-2011. Geneva, Switzerland: World Health Organization. 28 July 2010.
46. Fairley CK, Donovan B. What can surveillance of genital warts tell us? Sexual Health 2010; 7:325-327.
47. Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J Australia 2011; 124:1-8.
48. Read TRH, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women four years after commencing a national human papillomavirus (HPV) vaccination program. Sex Trans Inf 2011 [Epub ahead of print].
49. Immunise Australia Program, Human Papillomavirus (HPV) - The National HPV Vaccination Program Register. Australian Government, Department of Health & Ageing [Online]. 2011. http://www.immunise.health.gov.au/internet/immunise/ publishing.nsf/Content/immunise-hpv#figure1 [accessed 29 June 2011].
50. Brotherton JML, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377:2085-2092.
51. Grulich AE, Jin F, Conway EL, et al. Cancers attributable to human papillomavirus infection. Sex Health 2010; 7:244-252.
52. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010; 10:845-852.
53. Simatherai D, Bradshaw CS, Fairley CK, et al. What men who have sex with men think about the human papillomavirus vaccine. Sex Transm Infect 2009; 85:148-149.
54. ClinicalTrials.gov - U.S. National Institute of Health [Online]. 2011. http://clinicaltrials.gov/ [accessed 23 August 2011].
55. Brisson M, Van de Velde N, Boily MC. Different population-level vaccination effectiveness forHPVtypes 16, 18, 6 and 11.Sex TransmInfect 2010; 87:41-43.
56. Ditzian LR, David-West G, Maza M, et al. Cervical cancer screening in lowand middle-income countries. Mt Sinai J Med 2011; 78:319-326.
57. Natunen K, Lehtinen J, Namujju P, et al. Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries. Infect Dis Obstet Gynecol 2011; 2011:675858.